IBM, Pfizer launch joint experiment to assistance measure Parkinson’s symptoms using IoT and analytics

53
Source:   —  April 07, 2016, at 9:03 AM

Trying to track Parkinson’s symptoms is challenging today because they can vary widely throughout the day and doctors only look their patients on a periodic basis, says Ajay Royyuro, director of the Computational Biology Middle at IBM Research.

IBM, Pfizer launch joint experiment to assistance measure Parkinson’s symptoms using IoT and analytics

What happens when you keep a technology company together with a drug company and attempt to arrive up with unique new ways to realize Parkinson’s disease? You finish up with a project that uses sensors on the body and in the residence to allow continuous measurement of a patient’s symptoms and the impact they've on that person’s daily life, something that’s nearly impossible to do right now.

Trying to track Parkinson’s symptoms is challenging today because they can vary widely throughout the day and doctors only look their patients on a periodic basis, says Ajay Royyuro, director of the Computational Biology Middle at IBM Research. This makes any kind of meaningful measurement of the sickness a challenge for patients, doctors and researchers.

To compensate for this, doctors may ask patients to hold symptom diaries, but these can be spotty or subjective and can’t allow a complete objective picture of an individual patient’s specific set of symptoms when dealing with the sickness on a daily basis.

That’s why IBM and Pfizer have arrive up with this experiment, and it’s very much an experiment right presently to space sensors around the residence and on the body of an individual giving off a continuous stream of data, that'll be collected and compiled in some sort of data dashboard to create sense of the onslaught of information that a program love this could produce.

Pfizer’s role has to do with the drugs being used to treat the disease. Today, the dosage is an art and science trying to discover that perfect dosage pattern throughout a day. It’s impossible to do without a continuous assessment and the goal is that through these experiments the team can create a program that'd authorize that flow of data from the patient to their medical team and allow more pinpoint dosing.

“We have an opportunity to potentially redefine how we think about patient outcomes and twenty-four/seven monitoring, by combining Pfizer’s scientific, medical and regulatory expertise with IBM’s skill to integrate and interpret complex data in innovative ways,” Mikael Dolsten president of Pfizer Worldwide Research and Development said in a statement.

For starters, the experiment will get space at IBM’s research middle where they map to construct an experimental apt complete with kitchen, bathroom, bedroom and living room and start testing different sensors in the space, working with people who have Parkinson’s as well as healthy people to allow a clear view how a range of people react to this kind of measuring.

While the sensors in the living area would signal activities love entering a room, opening a cabinet and so forth, the body sensors would allow more precise measurements of the person’s action within the given room.

The hope is to eventually get this experiment out of the lab and discover an ideal sensor pack that’s cost-effective and simple to set up and support in a large no of houses. If they succeed, they'd conduct a genuine clinical trial, which Pfizer would assistance set up and administer.

Such a trial wouldn't just involve the sensors, but also the requirements of any clinical trial, Royyuro explained. The goal then would be not just to monitor symptoms, but measure how well a set of therapies would work when combined with the monitoring tools.

“The solution has to scale. It's as to be strong sufficient to deploy in patient’s residence and simultaneously do that in hundreds or even thousands of homes,” he explained.

IBM’s interest here isn’t strictly altruistic. It also sees a business opportunity involving huge data, analytics, the cloud and internet of things, but ultimately it's about improving the lives of people through technology.

“I think there is genuine opportunity here to create a disagreement in the lives of patients. I've seen and have near contact with a family member with Parkinson’s and I can look how effective it'd be to have this real-time symptomatic measurement and helping them create their lives better,” he said.

Featured Image: Kaspars Grinvalds/Shutterstock

READ ALSO
Samsung expects solid first-quarter results as the Galaxy S7 enjoys powerful sales

Samsung expects solid first-quarter results as the Galaxy S7 enjoys powerful sales

The company said it expects to report consolidated sales of about forty-nine trillion won and operating profit of about 6.6 trillion won in the first quarter of two thousand sixteen.

68
Sanders says Clinton not qualified to be president as war of words escalates in Democratic race

Sanders says Clinton not qualified to be president as war of words escalates in Democratic race

Bernie Sanders said his front-running rival Hillary Clinton was "not qualified" to be president because of "special-interest" contributions to her super PAC.

83
N Korea prepping large-caliber rocket launch system, S Korea says

N Korea prepping large-caliber rocket launch system, S Korea says

The announcement, reported in The WA Post, comes a day after a S Korean official said the N has the skill to mount a nuclear warhead on a medium-range missile that could strike targets in Russia, China, Japan and the Korean Peninsula.

80
What if the minimum wage expand is a fraud?

What if the minimum wage expand is a fraud?

Napolitano, a former judge of the Superior Ct of New Jersey, is the senior judicial analyst at Fox News Channel.

92